Logo image of UTHR

UNITED THERAPEUTICS CORP (UTHR) Stock Fundamental Analysis

NASDAQ:UTHR - Nasdaq - US91307C1027 - Common Stock - Currency: USD

307.65  -1.07 (-0.35%)

After market: 302.5 -5.15 (-1.67%)

Fundamental Rating

7

UTHR gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 560 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making UTHR a very profitable company, without any liquidiy or solvency issues. UTHR is valued quite cheap, while showing a decent growth score. This is a good combination! These ratings would make UTHR suitable for value and quality investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

9

1. Profitability

1.1 Basic Checks

UTHR had positive earnings in the past year.
In the past year UTHR had a positive cash flow from operations.
Each year in the past 5 years UTHR has been profitable.
Each year in the past 5 years UTHR had a positive operating cash flow.
UTHR Yearly Net Income VS EBIT VS OCF VS FCFUTHR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

1.2 Ratios

With an excellent Return On Assets value of 15.63%, UTHR belongs to the best of the industry, outperforming 96.09% of the companies in the same industry.
UTHR has a better Return On Equity (17.79%) than 95.91% of its industry peers.
Looking at the Return On Invested Capital, with a value of 16.27%, UTHR belongs to the top of the industry, outperforming 96.62% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for UTHR is in line with the industry average of 15.80%.
The last Return On Invested Capital (16.27%) for UTHR is above the 3 year average (14.96%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 15.63%
ROE 17.79%
ROIC 16.27%
ROA(3y)14%
ROA(5y)12.47%
ROE(3y)16.72%
ROE(5y)15.47%
ROIC(3y)14.96%
ROIC(5y)13.31%
UTHR Yearly ROA, ROE, ROICUTHR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20 30 40

1.3 Margins

With an excellent Profit Margin value of 40.44%, UTHR belongs to the best of the industry, outperforming 98.58% of the companies in the same industry.
UTHR's Profit Margin has improved in the last couple of years.
With an excellent Operating Margin value of 49.25%, UTHR belongs to the best of the industry, outperforming 99.47% of the companies in the same industry.
In the last couple of years the Operating Margin of UTHR has grown nicely.
Looking at the Gross Margin, with a value of 89.00%, UTHR belongs to the top of the industry, outperforming 91.46% of the companies in the same industry.
In the last couple of years the Gross Margin of UTHR has remained more or less at the same level.
Industry RankSector Rank
OM 49.25%
PM (TTM) 40.44%
GM 89%
OM growth 3Y7.2%
OM growth 5Y2.85%
PM growth 3Y13.74%
PM growth 5YN/A
GM growth 3Y-1.27%
GM growth 5Y-0.58%
UTHR Yearly Profit, Operating, Gross MarginsUTHR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60 80

More info and screens

8

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), UTHR is creating some value.
The number of shares outstanding for UTHR has been reduced compared to 1 year ago.
The number of shares outstanding for UTHR has been increased compared to 5 years ago.
Compared to 1 year ago, UTHR has an improved debt to assets ratio.
UTHR Yearly Shares OutstandingUTHR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
UTHR Yearly Total Debt VS Total AssetsUTHR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.2 Solvency

UTHR has an Altman-Z score of 11.77. This indicates that UTHR is financially healthy and has little risk of bankruptcy at the moment.
UTHR's Altman-Z score of 11.77 is amongst the best of the industry. UTHR outperforms 89.68% of its industry peers.
There is no outstanding debt for UTHR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.18
Altman-Z 11.77
ROIC/WACC1.7
WACC9.57%
UTHR Yearly LT Debt VS Equity VS FCFUTHR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2B 4B 6B

2.3 Liquidity

UTHR has a Current Ratio of 5.46. This indicates that UTHR is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of UTHR (5.46) is comparable to the rest of the industry.
A Quick Ratio of 5.23 indicates that UTHR has no problem at all paying its short term obligations.
The Quick ratio of UTHR (5.23) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 5.46
Quick Ratio 5.23
UTHR Yearly Current Assets VS Current LiabilitesUTHR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

More info and screens

5

3. Growth

3.1 Past

UTHR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 18.49%, which is quite good.
UTHR shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 16.88% yearly.
The Revenue has grown by 19.85% in the past year. This is quite good.
Measured over the past years, UTHR shows a quite strong growth in Revenue. The Revenue has been growing by 14.71% on average per year.
EPS 1Y (TTM)18.49%
EPS 3Y34.86%
EPS 5Y16.88%
EPS Q2Q%7.46%
Revenue 1Y (TTM)19.85%
Revenue growth 3Y19.52%
Revenue growth 5Y14.71%
Sales Q2Q%17.22%

3.2 Future

The Earnings Per Share is expected to grow by 18.63% on average over the next years. This is quite good.
UTHR is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.45% yearly.
EPS Next Y14.68%
EPS Next 2Y8.6%
EPS Next 3Y5.67%
EPS Next 5Y18.63%
Revenue Next Year12.24%
Revenue Next 2Y9.1%
Revenue Next 3Y7.23%
Revenue Next 5Y7.45%

3.3 Evolution

The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
UTHR Yearly Revenue VS EstimatesUTHR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1B 2B 3B 4B
UTHR Yearly EPS VS EstimatesUTHR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 20 40 60

More info and screens

8

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 12.28, which indicates a correct valuation of UTHR.
Based on the Price/Earnings ratio, UTHR is valued cheaply inside the industry as 96.44% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of UTHR to the average of the S&P500 Index (25.91), we can say UTHR is valued rather cheaply.
UTHR is valuated reasonably with a Price/Forward Earnings ratio of 10.60.
Based on the Price/Forward Earnings ratio, UTHR is valued cheaper than 95.91% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of UTHR to the average of the S&P500 Index (21.77), we can say UTHR is valued rather cheaply.
Industry RankSector Rank
PE 12.28
Fwd PE 10.6
UTHR Price Earnings VS Forward Price EarningsUTHR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

UTHR's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. UTHR is cheaper than 98.75% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, UTHR is valued cheaply inside the industry as 97.15% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 12.3
EV/EBITDA 6.02
UTHR Per share dataUTHR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 50 100 150

4.3 Compensation for Growth

UTHR's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
UTHR has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)0.84
PEG (5Y)0.73
EPS Next 2Y8.6%
EPS Next 3Y5.67%

More info and screens

0

5. Dividend

5.1 Amount

UTHR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

UNITED THERAPEUTICS CORP

NASDAQ:UTHR (5/23/2025, 9:01:28 PM)

After market: 302.5 -5.15 (-1.67%)

307.65

-1.07 (-0.35%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-30 2025-04-30/bmo
Earnings (Next)07-29 2025-07-29/amc
Inst Owners101.21%
Inst Owner Change-28.11%
Ins Owners1.76%
Ins Owner Change-11.82%
Market Cap13.88B
Analysts79
Price Target399.49 (29.85%)
Short Float %4.44%
Short Ratio4.11
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-2.14%
Min EPS beat(2)-3.83%
Max EPS beat(2)-0.45%
EPS beat(4)0
Avg EPS beat(4)-4.28%
Min EPS beat(4)-10.35%
Max EPS beat(4)-0.45%
EPS beat(8)4
Avg EPS beat(8)1.33%
EPS beat(12)6
Avg EPS beat(12)-3.77%
EPS beat(16)8
Avg EPS beat(16)-1.5%
Revenue beat(2)1
Avg Revenue beat(2)2.45%
Min Revenue beat(2)-1.81%
Max Revenue beat(2)6.71%
Revenue beat(4)3
Avg Revenue beat(4)1.96%
Min Revenue beat(4)-1.81%
Max Revenue beat(4)6.71%
Revenue beat(8)7
Avg Revenue beat(8)4.04%
Revenue beat(12)8
Avg Revenue beat(12)1.96%
Revenue beat(16)11
Avg Revenue beat(16)2.85%
PT rev (1m)-2.03%
PT rev (3m)-3.09%
EPS NQ rev (1m)1.28%
EPS NQ rev (3m)-2.87%
EPS NY rev (1m)-0.11%
EPS NY rev (3m)-0.13%
Revenue NQ rev (1m)2.84%
Revenue NQ rev (3m)0.69%
Revenue NY rev (1m)2.62%
Revenue NY rev (3m)1.64%
Valuation
Industry RankSector Rank
PE 12.28
Fwd PE 10.6
P/S 4.64
P/FCF 12.3
P/OCF 9.83
P/B 2.04
P/tB 2.07
EV/EBITDA 6.02
EPS(TTM)25.06
EY8.15%
EPS(NY)29.01
Fwd EY9.43%
FCF(TTM)25.02
FCFY8.13%
OCF(TTM)31.3
OCFY10.17%
SpS66.37
BVpS150.9
TBVpS148.43
PEG (NY)0.84
PEG (5Y)0.73
Profitability
Industry RankSector Rank
ROA 15.63%
ROE 17.79%
ROCE 21%
ROIC 16.27%
ROICexc 30.87%
ROICexgc 31.83%
OM 49.25%
PM (TTM) 40.44%
GM 89%
FCFM 37.69%
ROA(3y)14%
ROA(5y)12.47%
ROE(3y)16.72%
ROE(5y)15.47%
ROIC(3y)14.96%
ROIC(5y)13.31%
ROICexc(3y)29.18%
ROICexc(5y)24.89%
ROICexgc(3y)30.03%
ROICexgc(5y)25.71%
ROCE(3y)19.31%
ROCE(5y)17.18%
ROICexcg growth 3Y23.22%
ROICexcg growth 5Y4.92%
ROICexc growth 3Y22.46%
ROICexc growth 5Y5.97%
OM growth 3Y7.2%
OM growth 5Y2.85%
PM growth 3Y13.74%
PM growth 5YN/A
GM growth 3Y-1.27%
GM growth 5Y-0.58%
F-Score7
Asset Turnover0.39
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.18
Debt/EBITDA 0
Cap/Depr 366.37%
Cap/Sales 9.46%
Interest Coverage 44.68
Cash Conversion 90.97%
Profit Quality 93.22%
Current Ratio 5.46
Quick Ratio 5.23
Altman-Z 11.77
F-Score7
WACC9.57%
ROIC/WACC1.7
Cap/Depr(3y)347.88%
Cap/Depr(5y)280.91%
Cap/Sales(3y)8.54%
Cap/Sales(5y)7.36%
Profit Quality(3y)85.86%
Profit Quality(5y)98.64%
High Growth Momentum
Growth
EPS 1Y (TTM)18.49%
EPS 3Y34.86%
EPS 5Y16.88%
EPS Q2Q%7.46%
EPS Next Y14.68%
EPS Next 2Y8.6%
EPS Next 3Y5.67%
EPS Next 5Y18.63%
Revenue 1Y (TTM)19.85%
Revenue growth 3Y19.52%
Revenue growth 5Y14.71%
Sales Q2Q%17.22%
Revenue Next Year12.24%
Revenue Next 2Y9.1%
Revenue Next 3Y7.23%
Revenue Next 5Y7.45%
EBIT growth 1Y16.99%
EBIT growth 3Y28.12%
EBIT growth 5Y17.97%
EBIT Next Year17.96%
EBIT Next 3Y3.92%
EBIT Next 5Y-4.6%
FCF growth 1Y56.32%
FCF growth 3Y31.3%
FCF growth 5YN/A
OCF growth 1Y58.88%
OCF growth 3Y30.42%
OCF growth 5YN/A